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Abstract
The human heart is a target organ for the octapeptide hormone,
angiotensin II (Ang II). Recent studies suggest that the human
heart contains a dual pathway of Ang II formation in which the
major Ang II-forming enzymes are angiotensin I-converting
enzyme (ACE) and chymase. Human heart chymase has re-
cently been purified and its cDNA and gene cloned. This car-
diac serine proteinase is the most efficient and specific Ang
Il-forming enzyme described. To obtain insights into the car-
diac sites of chymase-dependent Ang II formation, we exam-
ined the cellular localization and regional distribution of chy-
mase in the human heart. Electron microscope immunocyto-
chemistry using an anti-human chymase antibody showed the
presence of chymase-like immunoreactivity in the cardiac in-
terstitium and in cytosolic granules of mast cells, endothelial
cells, and some mesenchymal interstitial cells. In the cardiac
interstitium, chymase-like immunoreactivity is associated with
the extracellular matrix. In situ hybridization studies further
indicated that chymase mRNA is expressed in endothelial cells
and in interstitial cells, including mast cells. Tissue chymase
levels were determined by activity assays and by Western blot
analyses. Chymase levels were approximately twofold higher in
ventricles than in atria. There were no significant differences in
chymase levels in ventricular tissues obtained from nonfailing
donor hearts, failing ischemic hearts, or hearts from patients
with ischemic cardiomyopathy. These findings suggest that a
major site of chymase-dependent Ang II formation in the heart
is the interstitium and that cardiac mast cells, mesenchymal
interstitial cells, and endothelial cells are the cellular sites of
synthesis and storage of chymase. In the human heart, because
ACE levels are highest in the atria and chymase levels are
highest in ventricles, it is likely that the relative contribution of
ACE and chymase to cardiac Ang II formation varies with the
cardiac chamber. Such differences may lead to differential sup-
pression of cardiac Ang II levels during chronic ACE inhibitor
therapy in patients with congestive heart failure. (J. Clin. In-
vest. 1993. 91:1269-1281.) Key words: angiotensin I-convert-
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Introduction
In blood, angiotensin II (Ang II)' is produced by the sequential
processing of angiotensinogen by renin and by angiotensin I-
converting enzyme (ACE) ( 1 ). Ang II is a vasoconstrictor hor-
mone ( 1 ), and drugs that inhibit ACE are potent antihyperten-
sive agents (2). ACE inhibitors are also very effective in the
treatment of congestive heart failure (3, 4). It is generally be-
lieved that the vasodilator effect of ACE inhibitors that pro-
duces a marked unloading of the failing heart is paramount to
its beneficial effect (5). Recently, some investigators have pro-
posed that direct cardiac effects ofACE inhibitors may also be
therapeutically important (6).
Numerous studies have indicated that Ang II has multiple
actions on the heart (7). It produces a positive inotropic and
chronotropic effect by a direct action on cardiac myocytes and
by stimulating the release ofnorepinephrine from cardiac sym-
pathetic nerves. Consistent with these effects ofAng II, we have
shown that Ang II receptors are present on atrial and ventricu-
lar myocytes and on cardiac sympathetic nerves in human
heart tissue (8). Others have shown that nanomolar concentra-
tions of Ang II produce a positive inotropic effect on isolated
human cardiac trabeculae (9, 10). Studies on cells in culture
show that Ang II is a cardiac growth factor ( 11). These studies
clearly suggest that the human heart is a target organ for Ang II.
Paracrine regulation ofhuman heart function by Ang II has
been proposed, but the enzymatic pathways of Ang II forma-
tion in the human heart are only now being addressed ( 12, 13).
Such studies are important in understanding the mechanism of
action ofACE inhibitors in patients with congestive heart fail-
ure. Our recent studies indicate that the human cardiac ventri-
cles contain a dual enzymatic pathway for Ang II formation in
which ACE-dependent Ang II formation is minor (- 10%)
compared to a major serine proteinase-dependent Ang II for-
mation ('- 80%) (12). We have isolated and sequenced this
serine proteinase, a novel enzyme that is not inhibited by ACE
inhibitors, and we have cloned its cDNA and gene ( 13, 14).
This novel proteinase is the most efficient and specific Ang
II-forming enzyme described ( 13, 15) and is the first struc-
turally characterized human member of the chymase group of
enzymes. To gain insights into factors that may regulate chy-
mase expression and to delineate potential sites ofchymase-de-
pendent Ang II formation in the heart, we examined the re-
gional distribution and the subcellular localization of human
1. Abbreviations used in this paper: Ang, angiotensin; ACE, angioten-
sin I-converting enzyme; EM, electron microscopy.
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heart chymase. Our results indicate that the cardiac intersti-
tium may be an important site of Ang II formation in the hu-
man heart, and that several cell types, including the cardiac
mast cell and endothelial cell, are the sites of biosynthesis and
storage ofchymase. Because Ang II has also been implicated in
the pathogenesis of congestive heart failure, we have addition-
ally examined levels of chymase-like activity and chymase
mRNA in normal and failing human hearts.
Methods
Human tissue. Nonfailing donor hearts (n = 13) were obtained from
LifeBanc (Cleveland, OH). These hearts, from 10 men and 3 women
ranging in age from 16 to 48 yr, were unsuitable for donation. Diseased
human hearts (n = 15), excised from patients undergoing cardiac
transplantation at the Cleveland Clinic Foundation, were the source of
failing heart tissue. Each of these diseased hearts was from a patient
with end-stage congestive heart failure accompanied by underlying cor-
onary artery disease; the patients were characterized as either ischemic
(n = 5; four male and one female, 39 to 57 yr), or dilated idiopathic
cardiomyopathy without active myocarditis (n = 10, seven males and
three females). All heart tissue was kept in cold cardioplegia solution
from the time of removal and frozen within 2 h. Healthy human tissue
including lung, liver, skin, kidney, and spleen were obtained from
various patients undergoing surgical procedures at the Cleveland Clinic
Foundation. The use of these tissues was approved by The Cleveland
Clinic Foundation's Internal Review Committee, and consent was ob-
tained from the donor or from his/her relatives or legal next of kin.
Electron microscopy (EM) immunocytochemistry. EM immunocy-
tochemistry was carried out according to the method ofWolosewick et
al. ( 16) with slight modification. Small pieces (0.5 cm cubic) of tissue
obtained from one nonfailing donor and one ischemic failing heart
were fixed within 2 h from the excision in 0.1 M cacodylate buffer, pH
7.3, containing 4% paraformaldehyde at 4VC overnight. Tissues were
further fixed in the same buffer containing 4% paraformaldehyde and
3% acrolein for 10 min. Then the samples were postfixed in the same
buffer containing 4% paraformaldehyde and 0.25% glutaraldehyde for
1 h. The samples were washed and dehydrated by a graded series < 80%
ethanol. The samples were infiltrated, embedded in acrylic resin (LR
White; Electron Microscopy Sciences, Fort Washington, PA), and
blocked out in gelatin capsules. Blocks were polymerized for 48 h at
50°C. A tissue block was sectioned on an RMC 6000 ultramicrotome,
and sections were mounted on 200 mesh formvar supported nickel
grid. Immunolabeling experiments and controls were repeated four
times with ventricular tissue and two times with atrial tissue. Over 20
grids were examined. The surface ofthe sections was first etched in 1 ml
freshly prepared saturated sodium metaperiodate at 22°C for 15 min.
This was followed by a rinse in distilled water, an exposure for 10 min
to I ml of 0. IN HCI, and another rinse in distilled water. Sections on
the grids were then exposed to 0.5 M ammonium chloride in 1 ml of
PBS, pH 7.4, for 30 min. These grids were preincubated in 600 Ad of20
mM Tris-HCI, pH 8.2, containing 0.1% BSA and 5% normal goat
serum. They were incubated with the diluted ( 100X ) antiserum against
human heart chymase ( 13) or with the diluted preimmune serum
( 100x) in the same buffer containing 0.1% BSA and 1% normal goat
serum at 22°C overnight. After several washes in the same buffer, these
grids were incubated with 10 nm gold conjugated goat anti-rabbit anti-
body (GAR IgG Au10; Amersham Corp., Arlington Heights, IL) di-
luted (30x) in the same buffer at 22°C for 3 h. At the end ofincubation
these grids were washed several times by the same buffer and exten-
sively washed by distilled water. Samples on the grids were contrasted
with 1% uranyl acetate (Electron Microscopy Sciences) and were exam-
ined and photographed in an electron microscope (model EM 10; Carl
Zeiss, Inc., Thornwood, NY) at 60 KV with an objective aperture of 30
Mm for photographs. Astigmatism caused by the magnetism of the
nickel grids was checked and adjusted for each grid.
In situ hybridization. Human heart tissues were fixed in 2% para-
formaldehyde in Ca2"/Mg2+-free PBS, pH 7.4, and 5-Mm paraffin sec-
tions were prepared on poly-L-lysine-pretreated microslides. 10 sec-
tions from each chamber ofone donor heart from a 26-yr-old male and
one recipient heart from a 34-yr-old male with idiopathic cardiomyopa-
thy were examined. An antisense oligonucleotide DNA probe
corresponding to a unique 13-residue sequence of human chymase
(+17-+29; see reference 14) and its corresponding sense probe were
synthesized: CTACCTGGAAATTGTAACTTCCAACGGTCCCTC-
AAAATTT, 126-165bp,sense-strand;AAATTTTGAGGGACCGTT-
GGAAGTTACAATTTCCAGGTAG, 165-126 bp, antisense strand
in the human heart chymase cDNA (14). After purification, probes
were 5'end labeled with Y[132P] ATP (specific activity 1 X I09 dpm/
Mg DNA). Hybridization was performed as previously described (17).
Sections were incubated in 20 mM Tris-HCI, pH 7.4, containing 1
,gg/ml of proteinase K (type 28; Sigma Chemical Co., St. Louis, MO)
and 2 mM CaCI2 for 30 min at 370C after removal of paraffin with
xylene. The tissue section was treated with 0.1 M triethanolamine, pH
8.0, for 2 min at 220C and with 0.25% (vol/ vol) acetic anhydride in 0.1
M triethanolamine, pH 8.0, for 10 min at 22°C. The radiolabeled
probes were incubated with the tissue sections (5 ng/section) in 10
mM Tris-HC1 buffer, pH 7.5, containing 300mM NaCI, 1 mM EDTA,
70% formamide (vol/vol), 2% dextran sulfate, 250 gg/ml salmon
testes DNA, and 250 ,g/ml yeast transfer RNA for 20 hr at 42°C. The
sections were then washed twice in 0.3 M NaCl/ 30 mM sodium citrate
for 30 min at 45°C and once for 60 min at 50°C. Slides were then
coated with Ilford K.2 nuclear track emulsion and left at -20°C for 3
wk. Autoradiographic grains were developed using Kodak D-19, and
the tissue was counterstained with hematoxylin and eosin Y. Adjacent
sections were also stained by Malloney's alcian blue method (18). Ra-
diolabeled oligonucleotide sense probe was also used as an indicator of
background and nonspecific binding.
Southern blot analyses ofhuman genomic DNA. Southern blot anal-
yses of human genomic DNA were carried out by a method previously
reported (14). 7 Mg of each leukocyte DNA prepared from three
healthy volunteers was digested by the restriction enzymes EcoRI,
EcoRl + Xbal, Rsal, Pstl, Pvu2, Hind3, or Sacd, and the resulting
fragments were resolved by 0.7% agarose gel electrophoresis. Frag-
ments that hybridized the full-length human heart chymase cDNA
probe that was 32P-labeled by random priming were then identified by
Southern blot analyses. To identify the additional fragment, if any,
which is not expected based on the restriction map of the human chy-
mase gene, the analyses were performed under low stringent wash con-
ditions (2 x SSC, 0.1% SDS, 45°C). The patterns of restriction frag-
ments ofeach blot from three different normal healthy volunteers were
compared.
Northern blot analyses. Poly (A)+RNA was isolated from I g of
human heart tissue using a poly (A)+RNA extraction kit (Fasttrack;
Invitrogen, San Diego, CA). Poly (A)+RNA was denatured in 6.5%
formaldehyde/50% formamide at 65°C, size-fractionated on a 1.2%
agarose gel containing 0.66% formaldehyde, and transferred to nitro-
cellulose membrane, as described by Maniatis et al. (19). After cross-
linking by ultraviolet irradiation, these blots were analyzed using a
full-length 32P-cDNA probe of human heart chymase (14) under
highly stringent washing conditions (0.1 x SSC, 0.1% SDS, 65°C). To
compare nonfailing and the idiopathic cardiomyopathic hearts, levels
of the human heart chymase mRNA expression were normalized by
the level of a-actin expression (cytoskeleton type) in the same blots.
Western blot analyses. The extraction of chymase from each tissue
was performed as follows: A halfgram of each tissue was homogenized
in 20 mM Tris-HCl buffer, pH 7.4, and centrifuged at 40,000 g for 20
min. This procedure was repeated twice. The pellet was resuspended in
20 mM Tris-HCl buffer, pH 8.0, containing 2.0 M KCl and 1% Triton
X-100, and incubated with gentle shaking at 4°C overnight. The mix-
ture was centrifuged as above, and the resultant supernatant was incu-
bated with 50 Ml of soybean trypsin inhibitor immobilized-agarose sus-
pension (Pierce Chemical Co., Rockford, IL). After extensive washing
of the soybean trypsin inhibitor-agarose gel with 20 mM Tris-HCI
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buffer, pH 8.0, containing 2 M KCI and the same buffer without KCI,
chymase bound to the gel was solubilized in 60 Al ofSDS-PAGE sam-
ple loading buffer at 220C overnight. The protein solubilized in SDS-
PAGE loading buffer and pure human heart chymase (100 and 200 ng
standard) ( 13) were electrophoresed on 14% SDS-polyacrylamide gels,
and the proteins were then transferred to a polyvinylidene difluoride
microporous membrane using SEMI-PHOR TE 70 purchased at
Hoefer Scientific Instruments (San Francisco, CA). The membranes
containing the electroblotted proteins were analyzed by Western blot
analyses using 1251 protein A, as previously described ( 13 ).
Enzymatic assayfor chymase-like activity in human tissues. A half
gram ofeach tissue was homogenized as described above, and the pellet
was resuspended in 2 ml of20 mM Tris-HCI buffer, pH 8.0. 5 Al sam-
ples, preincubated for 30 min at room temperature with I mM EDTA,
1 mM o-phenanthroline, 20 AM aprotinin, and with or without 10 gM
chymostatin, were incubated for 60 min at 370C with 10 nmol Ang I in
50 ,d of 20 mM Tris-HC1 buffer, pH 8.0, containing 0.5 M KCI and
0.01% Triton X-100. Generated Ang II was analyzed using a C18 re-
verse-phase HPLC column (Vydac, Hesperia, CA) ( 13, 15). The peak
area corresponding to a synthetic Ang II standard was integrated to
calculate Ang II formation. Chymostatin-inhibitable Ang II formation
was considered to represent the chymase-like activity and was ex-
pressed as nanomoles of Ang II formed/minute per gram tissue (wet
weight). Other known Ang II-forming enzymes including ACE, cath-
epsin G, kallikrein, chymotrypsin, trypsin, and carboxypeptidases were
completely inhibited in this assay procedure (data are not shown).
Statistical analyses. Autoradiographic data were analyzed using a
densitometric image analyzer (densitometer) driven by a MacIntosh
computer. To normalize the peak area, the value ofthe area ofinterest
was divided by the corresponding value ofthe denominator. In North-
ern blot analyses of nonfailing and idiopathic cardiomyopathic hearts,
a-actin was used as a denominator, and, in Western blot analyses,
standardized amounts (100 and 200 ng) of the purified human heart
chymase were used as a denominator. In analyzing the arbitrary unit
value for the two transcripts resulting from Northern blot analyses,
one-way ANOVA and Wilcoxon rank-sum tests were used for compar-
ing nonfailing and idiopathic cardiomyopathic hearts. In analyzing
chymase-like immunoreactivity and activity in the four chambers, a
paired t test was used for comparing the chambers. In addition to this
analysis, a mixed model analysis of variance was used with heart as a
random effect and the fixed effects representing the chamber type (ven-
tricle vs atrium) and side (left vs right). In the analyses ofchymase-like
immunoreactivity in the middle region of the left ventricular free wall
among nonfailing, ischemic, and idiopathic cardiomyopathic hearts,
one-way ANOVA, and Kruskal-Wallis tests were used for making the
comparisons among the groups. P < 0.05 was considered statistically
significant.
Results
EM immunocytochemical localization ofchymase in the hu-
man heart. To examine the cellular localization ofchymase in
the human heart, EM immunocytochemical studies with a spe-
cific polyclonal antibody for human heart chymase were per-
formed. Fig. 1 shows the localization of 10-nm immuno-gold
deposits on some but not all secretory granules of a cardiac
mast cell. The degree of immuno-gold labeling in these mast
cell granules was generally low. Mast cell granules that con-
tained the immuno-gold deposits had a dense core structure
surrounded by a translucent area with a lattice structure similar
to that of the tryptase/chymase (TC)-type mast cell (20, 21 ).
EM-immunocytochemical studies, such as those ofCraig et al.
(21 ), have also shown that human chymase is stored in mast
cell granules but that the degree of labeling ofthe TC type mast
cell granules with a human chymase antibody is relatively weak
and in some cases absent. The low degree of labeling could be
caused by a tight packing within granules ofchymase, heparin,
and other granule components (22). This type ofpacking may
limit antigen presentation. As is apparent in Fig. 1, once re-
leased, contents of the mast cell granules show a much higher
degree of labeling for chymase, which may occur because ofan
improvement in antigen presentation.
Immuno-gold deposits were also observed in cytosolic
granules ofendothelial cells located in intramural capillary. An
example of this is shown in Fig. 2. The immuno-gold labeled
cytosolic granules in several endothelial cells contained a mi-
crotubular structure, which is a typical ultrastructure of Wei-
bel-Palade body containing von Willebrand factor (23). Cyto-
solic granules found in some mesenchymal cells ofthe left ven-
tricular interstitium were also labeled with the immuno-gold
deposits (Fig. 3). These mesenchymal cells were enriched in
endoplasmic reticulum and contained several vacuoles. These
ultrastructural properties are consistent with the properties of
actively dividing fibroblasts (24).
The majority ofimmuno-gold deposits was observed in the
cardiac interstitial region (Fig. 4 A). The immuno-gold de-
posits appeared to be associated with the extracellular matrix.
No significant immuno-gold deposits were observed in myo-
cytes or on the sarcolemmal membrane of any of the sections
examined (Fig. 4 A). A low level of immuno-gold deposits,
diffuse in pattern, was observed when preimmune serum was
used in place of antisera against human heart chymase (Fig. 4
B); this type oflabeling is characteristic ofnonspecific binding.
Localization ofchymase mRNA in the heart by in situ hy-
bridization. To examine whether the immuno-gold deposits
appearing in interstitial cell cytosolic granules are caused by
chymase synthesis in interstitial cells or to protein endocytosis,
in situ hybridization studies were carried out using a specific
human chymase oligonucleotide probe. Dark and bright field
views ofa right ventricular section shows that chymase mRNA
in the heart is localized in interstitial cells, as well as in endothe-
lial cells of intramural arterioles (Fig. 5). An adjacent section
stained by alcian blue for the identification ofmast cells shows
that several mast cells, but not the number equivalent to the
number ofchymase mRNA positive cells in Fig. 5 B, appeared
in the media and adventitia region of the same intramural ar-
teriole. Fig. 6 shows bright and dark field views of a section
stained by hematoxylin and eosin, showing that interstitial and
endothelial cells in intramural venula also contain chymase
mRNA. An adjacent section produced by the radiolabeled
sense probe shows low level and diffuse distribution of grains
characteristic of nonspecific binding (Fig. 6 C).
Southern blot analyses ofhuman genomic DNA. Southern
blot analyses were performed using seven different restriction
enzymes. One distinct hybridizing species is apparent in the
EcoRl, EcoRl + Xbal, Rsal, and Pstl digests; two in the Pvu2
and the Hind3 digests; and three in Sacd digest (Fig. 7). The
human chymase gene contains one Pvu2 site; two Sac 1 and
Hind3 sites; three Pstl sites but no EcoRl, Xbal, and Rsal
sites ( 14, 25). Since one Hind3 and two Pst 1 fragments in the
human chymase gene contain short encoding regions (76 bp,
50 bp, and 140 bp, respectively), these three fragments were
not capable of being visualized in this Southern blot analysis.
In all six different digests, however, there were no additional
bands from the number expected as a result of the restriction
map of the human chymase gene ( 14). These results suggest
that, unlike rodent chymases (26-28), human chymase is
likely to be a single gene product.
Human Heart Chymase 1271
w.4..^t''S'E''Dts,§Hi. A - b X ', ,
*. cst- a!g |g
..fWll!*, .*.... @w M~~~~~~~~~~~AVONa
a..
*~~~~~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~~~~.
.......
* I0.;t~~~~~~~~~~~~~~a.0000 In Ski o .tj . t;;;~~~~~~~~~~~~~~~~~~~~~~4iA-.!Aercn...
;ofS;0t i.: W0: * S 4 0 By i to110;~~~~~~~~~~~~~~~~~~~~~~~'3
Regional distribution ofchymase mRNA, chymase-like im-
munoreactivity, and activity in the human heart. An example of
Northern blot analyses of chymase mRNA in atria and ventri-
cles from a male donor is shown in Fig. 8. Two transcripts
(- 1.4 and - 0.9 kb) were identified for each chamber of the
heart and are likely caused by differential polyadenylation for
the following reasons: (a) these two bands were equally intense
even under highly stringent washing conditions; (b) the homol-
ogy at the nucleotide level of the closest member to human
heart chymase (e.g., cathepsin G or cytotoxic cell protease) is
c 50% (14); (c) human chymase is likely a single gene product
(see previous section); (d) only a single 769-bp polymerase
chain reaction product was obtained from the mRNA isolated
from the nonfailing or failing hearts ( 14); and (e) a single chy-
mase was purified to homogeneity from human heart tissue
( 13). However, an alternate promoter for the transcription or
an alternate splicing of the nascent transcript is possible. No
significant difference in the levels ofthese two chymase mRNA
transcripts was found between the nonfailing (n = 8) and the
Figure 1. Immunohistochemis-
try ofhuman left ventricular
tissue using antichymase anti-
body. This tissue sample was
from a donor heart of a 26-yr-
old male. Immuno-gold elec-
tron microscopy identifies chy-
mase-like immunoreactivity
to be localized in mast cell
granules (G, arrows). The cy-
tosolic region ofthis mast cell
is filled by large secretory gran-
ules that appear to have a dense
core structure surrounded by
a translucent area with a lattice
structure. Immuno-gold de-
posits are also localized in the
interstitial area (I). Bar, 500
nm.
failing idiopathic cardiomyopathic hearts (n = 10) (70±10 vs
51±6 arbitrary densitometric units for 1.4-kb bands, P = 0. 12;
38±13 vs 34±5 arbitrary densitometric units for 0.9-kb bands,
P = 0.74, respectively).
Northern blot analyses indicate that the ratio of the chy-
mase mRNA to poly (A)+RNA in each cardiac chamber is not
remarkably different (Fig. 8). Because there could be differ-
ences in the efficiency ofmRNA extraction between regions of
the heart, it is uncertain ifthe levels ofchymase mRNA among
cardiac chambers are similar or are different.
Regional differences in chymase-like immunoreactivity
and activity in each chamber of five nonfailing donor hearts
were estimated by Western blot analyses (Figs. 9 and lOA) and
enzymatic activity assays (Fig. 10 B). A significant correlation
was observed between chymase-like immunoreactivity and ac-
tivity in nonfailing donor heart tissue (y = 7.8x + 20, r2 = 0.54,
n = 18, P < 0.001) (Fig. 10 C). When analyses were done
according to chamber type (ventricles, n = 10, vs atria, n = 8 ),
both chymase-like immunoreactivity (P < 0.02) and activity
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Figure 2. Immunohistochemistry of an en-
dothelial cell from a cardiac intramural cap-
illary using antichymase antibody. This tissue
sample was from a donor heart ofa 26-yr-old
male. Immuno-gold electron microscopy
identifies chymase-like immunoreactivity to
be localized in endothelial cell granules (G,
arrow). This granule has an internal micro-
tubular structure, which is a typical of Wei-
bel-Palade body. Immuno-gold deposits are
also found in the interstitial region (I)
surrounding this endothelial cell. N, nucleus
ofendothelial cell; V, capillary lumen. Bar,
350 nm.
(P < 0.05) were approximately twofold higher in ventricles
than in atria (chymase-like immunoreactivity, ventricles
14±1.4 vs atria 6.9±1.1 arbitrary densitometric units, respec-
tively; chymase-like activity, ventricles 140±13 vs atria 61 ± 12
nmol Ang II formed/min per g tissue, respectively). When
analyses were done according to side ofthe heart (right, n = 10,
vs left, n = 8), there was no significant difference in chymase-
like immunoreactivity (P = 0.98) and activity (P = 0.41) be-
tween the right and the left heart (chymase-like immunoreac-
tivity, right 10± 1.5 vs left 1 1±2.0 arbitrary densitometric units,
respectively; chymase-like activity, right 105±21 vs left
102±14 nmol Ang II formed/min per g tissue, respectively).
A summary ofchymase-like immunoreactivity and activity
in nonfailing human left ventricular tissue and in left ventricu-
lar tissue from patients with ischemic or idiopathic cardiomy-
opathy is presented in Table I. There was no significant differ-
ence in chymase-like immunoreactivity (P = 0.45) and activity
(P = 0.45) among nonfailing, failing ischemic, and idiopathic
cardiomyopathy hearts.
A summary ofchymase-like immunoreactivity and activity
in several human tissue is presented in Table II. Levels of chy-
mase-like immunoreactivity and activity in the cardiac ventri-
cles, lung, and liver were generally higher than those of ob-
served in atria, coronary artery, aorta, kidney, and spleen. In
the skin, high level of chymase-like activity was observed, but
levels ofchymase-like immunoreactivity were low. It is, at pres-
ent, unclear whether skin tissue contains high levels ofan Ang
II-forming enzyme that is immunologically dissimilar to chy-
mase.
Discussion
Our recent studies with human heart tissue suggest the pres-
ence ofa dual pathway ofAng II formation in which the serine
proteinase chymase is the major and ACE is the minor Ang
II-forming activity ( 12). Chymase isolated from the human
heart has a high catalytic efficiency and specificity for the con-
version of Ang I to Ang II, and has been proposed to play a
significant role in the paracrine regulation of heart function by
Ang 11 (12, 13). In this report, we describe the cells in the
human heart that are involved in the synthesis ofchymase and
the localization of this enzyme once it is released. These obser-
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Figure 5. (A) Dark field view
ofa histological section of the
right ventricle from a donor
heart of a 26-yr-old male hy-
bridized with a human chy-
mase-antisense oligonucleotide
probe. Bright spots represent
human chymase mRNA. Sev-
eral adventitial interstitial cells
containing human chymase
mRNA are indicated (white
arrowheads). (B) An alcian
blue stained histological sec-
tion, adjacent to that shown
in (A), indicates mast cells
(black arrows). X200.
vations, as well as a systematic study of the regional distribu-
tion ofchymasein the human heart, provide valuable insights
into the role of chymase in cardiac Ang II formation.
EM-immunocytochemical studies using a specific human
heart chymase polyclonal antibody indicate the presence of
chymase-like immunoreactivity in secretory granules of hu-
man cardiac mast cells. This finding was expected, since all
other mammalian chymases studied have been shown to be
stored in an active form in secretory granules of the mast cell
(29, 30). A highly unexpected finding was the observation that
chymase-like immunoreactivity is present in Weibel-Palade
bodies of endothelial cells and in cytosolic granules of intersti-
tial mesenchymal cells. These interstitial cells appeared to be
actively dividing fibroblasts because of the presence of an ex-
tensive network ofrough endoplasmic reticulum and cytoplas-
mic vacuoles (24). The human heart chymase antibody used
in these subcellular localization studies did not cross-hybridize
to other known serine proteinases closely related to chymase
such as human neutrophil cathepsin G ( 13), suggesting that
the vesicular chymase-like immunoreactivity was caused by
chymase. To examine if unknown chymase-like proteinases
highly homologous to human chymase may contribute to chy-
mase-like immunoreactivity, Southern blot analyses ofhuman
genomic DNA were carried out using a cDNA probe compris-
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Figure 6. (A) Bright field and (B) dark field
views of a histological section of the right ven-
tricle from a donor heart ofa 26-yr-old male
hybridized with a human chymase-antisense
oligonucleotide probe. Silver grains in A or
bright spots in B represent human chymase
mRNA transcripts. Based on alcian blue stain-
ing of an adjacent section (not shown), the
heavily labeled interstitial cell indicated by an
arrow appears to be a mast cell. A high density
of silver grains are also found in endothelial
cells (arrowheads). (C) Dark field view of a
histological section, adjacent to that shown in
A, hybridized with a sense probe complimen-
tary to the probe used in A and B. The staining
ofthis tissue section by hematoxylin & eosin
was much weaker than that in B. Weak stain-
ing was necessary to show in a dark field view
that the brightly lit silver grains in this control
section had a diffuse pattern indicative of non-
specific binding. x 170.
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c
7-4 Figure 7. Southern blot
analyses ofhuman ge-
nomic DNA with hu-
+- man heart chymase
X4 P4 es W-.4 V-4 cDNA probe. 7 Ag ofO808 et human DNA were di-gested with restriction
kb enzymes, as listed on
the top of the figure.
-23.1 Fragments that hybrid-
ized the full-length 32p_
7.0 labeled human heart
chymase cDNA probe
401 Hi0 - 5.0 were identified by
- 4.0 Southern blot analyses.
The analyses was per-
- 3.0 formed under low strin-
gent washing condi-
W 2.0 tions, as described. One
. 2. distinct hybridizing spe-
- 1.6 cies is apparent in the
EcoRl, EcoRI + Xbal,
Rsal, and Pstl digests;
- 1.0 two in the Pvu2 and
Hind3 digests; and three
in the Sacd digest. The
human heart chymase
- 0.5 gene contains one Pvu2
site, two Sacd and
Hind3 sites, three Pstl
sites, but no Eco Rl,
Xbal, and Rsal sites.
Since one of the Hind3
and two of Pstl fragments contain the short encoding region (76, 50,
and 140 bp, respectively) of the human heart chymase gene, these
three fragments were not capable of being visualized in this Southern
blot analyses. Please note that, in any of six different digests including
Rsal, no additional bands other than those expected from the re-
striction map ofthe human heart chymase gene were found, suggest-
ing that there is a single gene for human chymase. This Southern
blot is representative of three different blots obtained using genomic
DNA from three humans.
ing the entire coding region of human heart preprochymase.
Extensive low stringency Southern blot analyses indicated that
human chymase is a single gene product, supporting the con-
tention that the human heart chymase antibody did not cross-
react with unknown proteins highly homologous to human
chymase. These observations indicate that the chymase-like
immunoreactivity detected in cytosolic granules of mast cells,
endothelial cells, and some interstitial cells is likely to be
caused by chymase.
Based on their ultrastructural characteristics, cytosolic vesi-
cles containing chymase-like immunoreactivity in mast cells
and endothelial cells, but not those ofinterstitial cells, appeared
to be secretory (31, 32). To clarify whether vesicular chymase-
like immunoreactivity in interstitial cells is a product of cellu-
lar biosynthesis or occurred through protein uptake, in situ
hybridization studies were carried out. Using a highly specific
antisense oligonucleotide probe, chymase mRNA signal was
observed in endothelial cells of the intramural venula and in
several interstitial cells including mast cells. These in situ hy-
bridization studies, as well as the EM-immunocytochemical
studies, are the first to show that human chymase is elaborated
dec) E
28 S
18 S-a
Figure 8. A representa-
kb tive Northern blot of
chymase mRNA ex-
4.40 pression in the human
-2.37 heart. Poly (A)+RNA
was isolated from one
- 1.35 gram of a nonfailing
donor heart and 3 gig of
poly (A)+RNA was
used for Northern blot
---0.24 analyses, as described.Exposure time for de-
velopment was 7 d. Two
transcripts ( - 1.4 and
- 0.9 kb) were ob-
served in each chamber
of the heart.
in cell types other than the mast cell. This is a unique finding,
since other known chymases have been described only in mast
cells (29, 30, 33). It is interesting to note that the 5' and 3'
untranslated region of human chymase gene lacks important
mast cell specific enhancer sequences found in mouse and rat
chymase genes ( 14, 25, 34). It is tempting to suggest that such
differences in the cis-acting elements of the human chymase
gene may account for its more widespread cellular distribution
than other mammalian chymases. Because chymases previ-
ously have only been identified in mast cells, they have often
been referred to as mast cell proteases; e.g., rat mast cell pro-
tease I, rat mast cell protease 11 (29, 30). Because chymase is
present in multiple cell types in the human heart, we believe
Figure 9. A representa-
.@ -c) gtive Western blot show-
ing chymase-like immu-
noreactivity in the hu-
= P CUc; man heart.A half gram
of tissue from each
chamber of a donor
X=kD heart was analyzed for
chymase-like immuno-
reactivity, as described
- 32.5 in Methods. A majorimmunoreactive band,
F
w-- 27.5 30 kD, was observedin each heart chamber,
- 185 Chowever, lower molecu-18.5 lar weight immunoreac-
tive bands of lesser in-
tensity were also ob-
served. We have
previously shown that human chymase remains active after proteo-
lytic cuts are made in noncritical regions of the enzyme ( 13 ). How-
ever once the enzyme is cut, it appears as a lower molecular weight
band when analyzed by SDS-PAGE under reducing conditions ( 13).
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Figure 10. Regional dis-
tribution of chymase-
like immunoreactivity
and activity in the hu-
man heart. Chymase-
like immunoreactivity
(ir) (A) and activity (B)
were determined in each
chamber of five nonfail-
ing hearts (two left atrial
tissue could not be ob-
tained), as described in
the Methods section.
Based on control de-
nominators (100 or 200
ng pure human heart
chymase), autoradio-
graphic data in Western
blots at 30 kD (size of
native human chymase
in the heart) were con-
verted to the arbitrary
densitometric units.
Horizontal bars repre-
sent mean values. (C)
A significant correlation
was observed between
chymase-like immuno-
reactivity and activity
(y = 7.8x + 20, r2
=0.54,n= 18).LV, left
ventricle; R V, right ven-
tricle; LA, left atrium;
RA, right atrium.
that the name chymase is more appropriate than the name
human mast cell protease, proposed by Jenne et al. (35). The
name "chymase" is not limiting as the name "mast cell pro-
tease."
Using EM-immunocytochemistry, Kaminer et al. (36)
have shown that chymase in isolated human skin mast cells is
released in the extracellular space 1 h after a 2,4-dinitrochloro-
benzene challenge; released chymase was observed attached to
the extracellular matrix. High levels of chymase-like immuno-
reactivity are localized in the cardiac interstitium and are likely
associated with the interstitial extracellular matrix. Human
chymase is a highly basic enzyme (14). Molecular modeling
studies on human chymase (Sung S. S., and A. Husain, unpub-
lished observations) indicate the presence of several positively
Table I. Chymase-like Immunoreactivity and Enzymatic Activity
in Left Midventricular Regions ofNonfailing
and Failing Human Hearts
Chymase-like Chymase-like
Pathological diagnosis immunoreactivity activity
arbitrary nmol Ang II
densitometric formed/minig
units tissue wet wt
Nonfailing (n = 5) 64±14 105±11
Ischemic cardiomyopathy (n = 5) 36±11 88±15
Idiopathic cardiomyopathy (n = 5) 54±20 100±12
Table II. Chymase-like Immunoreactivity and Enzymatic Activity
in Human Tissues
Chymase-like Chymase-like
Tissues immunoreactivity* activityt
Left ventricle +++ +++
Right ventricle +++ +++
Lung ++ +++
Liver ++ ++
Left atrium + ++
Right atrium + +
Coronary artery + ++
Aorta + +
Skin + +++
Kidney cortex + ++
Kidney medulla + +
Spleen ND +
* +, < 7.5; ++, 7.5 to 15; and +++, > 15 arbitrary densitometric
units. t +, < 30; ++, 30 to 70; and +++, > 70 nmol Ang II
formed/min per g tissue (wet wt). ND, not detectable.
charged residues on the surface of this enzyme. In rat chymase
I, these positively charged residues have been suggested to play
a role in binding to heparin or to other sulfated proteoglycans
and glycosaminoglycans found in secretory granules, and to
the extracellular matrix (37). The highly basic nature of hu-
man chymase is common to all known proteinases found in
mast cell granules including tryptase (38), carboxypeptidase A
(39) and cathepsin G (40). It is also known that when these
proteinases are bound to heparin or to heparan sulfate, they are
relatively resistant to proteolytic degradation and to inactiva-
tion by the plasma serine proteinase inhibitor (41 ). Chymase
in the heart may thus be relatively stable and likely remains
active after binding to the extracellular matrix. This latter con-
clusion is supported by the fact that human chymase is active
after binding to heparin immobilized on agarose (Urata, H.,
and A. Husain, unpublished observation). Ang II formation
occurring from chymase activity associated with the extracellu-
lar matrix in the cardiac interstitium may thus be a major site
of local Ang II formation in the human heart.
ACE inhibitors are widely used in the treatment of hyper-
tension and congestive heart failure (2, 3, 42). Because it is
presumed that Ang II levels in the failing heart are reduced
substantially after ACE inhibitor therapy, some investigators
believe that Ang II effects on the failing human heart are delete-
rious (6). The level of Ang II in human heart tissue is likely
regulated by two mechanisms: (a) uptake ofcirculating Ang II;
and (b) local conversion ofAng I to Ang II by ACE and poten-
tially by chymase. In blood serum, ACE is the major enzyme
that converts ofAng I to Ang 11 ( 12). By inhibiting ACE, Ang
II formation in the circulation will be markedly reduced. There-
fore, the fraction ofAng II in the heart that is taken up from the
circulation also will be markedly reduced. Local Ang II forma-
tion in the heart caused by human cardiac ACE will also be
reduced during ACE inhibitor therapy. On the other hand,
since chronic ACE inhibitor therapy produces a > 300% in-
crease in circulating Ang I levels (43), uptake of Ang I to the
heart should be increased. Because chymase levels also are not
reduced in cardiac ventricles ofpatients with idiopathic or isch-
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emic cardiomyopathy, it is tempting to speculate that chy-
mase-dependent conversion of Ang I to Ang II in heart tissue
will be increased in patients undergoing ACE inhibitor therapy.
We believe that the contribution ofACE and chymase to car-
diac Ang II formation needs to be determined before conclu-
sions are made about the role of cardiac Ang II in congestive
heart failure. Such information may prove to be valuable in
understanding the mechanism ofaction ofACE inhibitors and
Ang II receptor antagonists in the treatment of hypertension
and congestive heart failure, particularly if differences in effi-
cacy are apparent between these drug classes.
During chronic ACE inhibitor therapy levels of circulating
Ang II are only partially decreased (44). It has been suggested,
but not proven, that even high doses of ACE inhibitors, pro-
duce incomplete inhibition of tissue ACE. It is conceivable,
however, that during chronic ACE inhibitor therapy, Ang II
formed by chymase in the heart and possibly in other tissues
contributes to blood Ang II levels. To investigate the potential
contribution of tissue chymase in regulating circulating Ang II
levels, we determined the distribution of chymase in several
human tissues. The presence of chymase-like immunoreactiv-
ity and activity in the skin, lungs, liver, and coronary arteries
would suggest that tissues other than the heart may contribute
to levels of circulating Ang II observed during chronic ACE
inhibitor therapy. With respect to vascular chymase-like activ-
ity, it is interesting to note that Ang I-mediated contraction of
monkey mesenteric and pulmonary arterial strips has been re-
ported to be partially inhibited (by - 55%) by an ACE inhibi-
tor, but completely inhibited by combined ACE inhibitor and
chymostatin treatment (45). Chymostatin, a nonspecific inhib-
itor of chymotrypsin-like proteinases which inhibits human
chymase, could inhibit Ang I-mediated vascular contraction
by inhibiting chymase-like activity in monkey vessels.
Chymase-dependent Ang II formation may be greater in
human cardiac ventricles than in atria since our study shows a
twofold higher level ofchymase-like immunoreactivity and ac-
tivity in ventricles than in atria. ACE activity in the human
heart also shows regional variations ( 12). Levels of ACE are
approximately threefold higher in the right atrium than in the
left ventricle and are twofold higher in the right ventricle than
in the left. Under chronic ACE inhibitor therapy, differential
changes in cardiac Ang II concentration may occur. Because of
the relative distribution of ACE and chymase in the human
heart, atrial Ang II levels may be reduced more significantly
than left ventricular Ang II levels during chronic ACE inhibitor
therapy. In addition to regional differences in levels ofchymase
and ACE, differences in the enzymatic properties of chymase
and ACE may also be important. Chymase and ACE are highly
efficient Ang II-forming enzymes. However, unlike ACE, chy-
mase is more specific and does not cleave bradykinin and sub-
stance P (13, 15). This observation would suggest that chy-
mase-dependent Ang II formation is not coupled to the simulta-
neous inactivation of vasodilator peptides as has been shown
with ACE, a role perhaps more consistent with the regulation
of myocyte function than with blood pressure regulation.
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